AMGN News and Press, Amgen Inc. From 06/04/24

2024-06-04 07:30:00 ET Summary The obesity market is expected to reach $130 billion by 2030, benefiting companies like Eli Lilly and Novo Nordisk. Amgen, a biotech company, is experiencing innovation-fueled growth with impressive new products and international expansion. Amgen...

2024-06-04 04:20:17 ET Summary Cerevel Therapeutics agreed to be acquired by AbbVie on 12/06/23 for $45/s or ~$8.7B. CERE stock closed on Friday, May 31st at $40.74/s. This presents investors with a potential arbitrage play of over 10% on a deal that should close within the next 3...

AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif. , June 3, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:00 a.m. ET on Thursday , June 6, 2024. Peter Griffith...

2024-06-02 10:00:00 ET More on Amgen, Structure Therapeutics, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? ...

2024-06-01 06:40:25 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies withupcoming pay dates. Introduction The Di...

2024-05-31 13:22:01 ET Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts project significant growth in this sector, with Amgen among key players like Novo Nordisk and Eli Lilly. The U.S. FDA has approved Amge...

2024-05-30 16:10:00 ET Summary The global market for GLP-1 therapies now looks on pace to top $100 billion. GLP-1 pioneers such as Eli Lilly, Novo Nordisk, could be joined by new players Amgen, Altimmune, Pfizer, Viking, Roche, and privately held Boehringer Ingelheim that have GLP...

2024-05-30 11:22:06 ET More on Eli Lilly, Novo, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Lilly's Retevmo gains appro...

2024-05-29 13:01:37 ET More on Amgen, AstraZeneca Amgen Stock: Poised To Break Out (Technical Analysis) AstraZeneca, Amgen release mid-stage data on Tezspire for COPD Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo Amgen, Inc. (AMGN) ATS...

2024-05-29 11:50:26 ET More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca, Daiichi Sankyo ADC misses ke...